BSEM (BioStem Technologies) Total Current Liabilities: $12.2 Mil (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.30
GF Value $139.96
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Total Current Liabilities?

BioStem Technologies BSEM -5.17% 49 Total Current Liabilities is $12.2 Mil as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BioStem Technologies's total current liabilities for the quarter that ended in Sep. 2025 was $12.2

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BioStem Technologies Total Current Liabilities Related Terms

BioStem Technologies Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Total Current Liabilities Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.37 6.54 6.33 15.62 99.17

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.91 15.62 81.01 99.17 12.22
BSEM
49GF Score
BioStem Technologies Inc BSEM
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BioStem Technologies's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=94.394+4.064
+Other Current Liabilities+Current Deferred Liabilities
=0.712+0
=99.2

BioStem Technologies's Total Current Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.654+3.229
+Other Current Liabilities+Current Deferred Liabilities
=1.335+0
=12.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $12.2 Mil mean?
BioStem Technologies (BSEM) has a Total Current Liabilities of $12.2 Mil as of Sep. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors.
Is BioStem Technologies' Total Current Liabilities too high?
BioStem Technologies' current Total Current Liabilities is $12.2 Mil. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Total Current Liabilities compare to XLO and TCRX?
BioStem Technologies' Total Current Liabilities of $12.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for BioStem Technologies and its competitors. BioStem Technologies's current Total Current Liabilities is $12.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.30 — trading 97.6% below its estimated fair value. The current Total Current Liabilities is $12.2 Mil. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Total Current Liabilities is $12.2 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.30 is trading 97.6% below its estimated GF Value™ of $139.96. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Total Current Liabilities: $12.2 Mil
  • GF Value™: $139.96 vs. price of $3.30 (97.6% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price
$139.96
GF Value